Indegene has debuted at Rs 659.70 on the BSE, up by 207.70 points or 45.95% from its issue price of Rs 452.00.
The scrip is currently trading at Rs 541.45, up by 89.45 points or 19.79% from its issue price. It has touched a high and low of Rs 659.70 and Rs 527.80 respectively. So far 13.54 lakh shares were traded on the counter.
The offering, which was open for subscription between May 6, 2024 and May 8, 2024 was subscribed 70.30 times. The issue price was fixed at Rs 452 per share i.e. at upper end of price band of Rs 430-452 apiece.
Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 428.35 |
| Indegene | 491.95 |
| CMS Info Systems | 312.90 |
| JITF Infralogistics | 312.00 |
| Sagility | 42.16 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: